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Abstract Normal bone mineral accrual requires adequate
dietary intake of calcium, vitamin D and other nutrients;
hepatic and renal activation of vitamin D; normal hormone
levels (thyroid, parathyroid, reproductive and growth
hormones); and neuromuscular functioning with sufficient
stress upon the skeleton to induce bone deposition. The
presence of genetic or acquired diseases and the therapies
that are used to treat them can also impact bone health.
Since the introduction of clinical DXA in pediatrics in the
early 1990s, there has been considerable investigation into
the causes of low bone mineral density (BMD) in children.
Pediatricians have also become aware of the role adequate
bone mass accrual in childhood has in preventing osteopo-
rotic fractures in late adulthood. Additionally, the availabil-
ity of medications to improve BMD has increased with the
development of bisphosphonates. These factors have led to
the increased utilization of DXA in pediatrics. This review
summarizes much of the previous research regarding BMD
in children and is meant to assist radiologists and clinicians
with DXA utilization and interpretation.
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Abbreviations
ALL acute lymphocytic leukemia
BMC bone mineral content
BMD bone mineral density
CF cystic fibrosis
CS corticosteroids
DXA dual energy X-ray absorptiometry
JRA juvenile rheumatoid arthritis
LS lumbar spine
TBBMC total body bone mineral content
TBBMD total body bone mineral density
WBI whole brain irradiation
Introduction
Peak bone mineral accrual occurs during early puberty and
peak bone mass is achieved in young adulthood. Low BMD
can result from a wide variety of childhood diseases or be
due to the effects of their treatment. Increasingly, pediatric
specialists are requesting evaluation of BMD and radiol-
ogists are expected to be knowledgeable in the technique,
interpretation and clinical applications of DXA. A review
of the technical and interpretive aspects of DXA has been
recently presented [1]. The clinical uses of DXA in
pediatrics are exceedingly broad. This paper reviews the
clinical data regarding pediatric DXA and can be used to
assist radiologists and clinicians in DXA utilization and
interpretation.
Gastrointestinal disorders
Gastrointestinal diseases may impact bone health in several
ways. Poor calcium intake, as in patients with a milk
Pediatr Radiol (2007) 37:625–635
DOI 10.1007/s00247-007-0450-0
L. A. Binkovitz (*)
Department of Radiology, Columbus Children’s Hospital,
700 Childrens Way,
Columbus, OH, USA
e-mail: binkovitz@yahoo.com
P. Sparke
Department of Chemistry, Capital University,
Columbus, OH, USA
M. J. Henwood
Department of Endocrinology, Columbus Children’s Hospital,
Columbus, OH, USAallergy, and reduced calcium absorption, as in patients with
untreated celiac disease, result in low BMD. Early
correction of the underlying deficiency allows normal bone
mineralization to occur. In addition to poor calcium
absorption, inflammatory bowel disease likely impacts
bone health through other factors including chronic
diarrhea, decreased lean tissue mass, reduced physical
activity, increased inflammatory cytokines, and CS therapy.
As in all chronic conditions, correction of short stature and
delayed maturation will allow better identification of those
patients with abnormal DXA findings who will have
significant bone mineral deficits.
Milk allergy
Henderson and Hayes [2] reported a positive correlation
between LS and hip BMD and calcium intake in children
with significant milk allergy. They found a 5–8% increase
in LS Z-scores and a 9–13% increase in hip Z-scores in
patients with daily calcium intake above the recommen-
ded dietary allowances. These findings were confirmed in
children with reduced dairy intake due to a variety of
other causes [3, 4]. There was a positive correlation
between BMD and calcium intake with normal values in
the subgroup with normal dietary calcium intake and
decreasing BMD as the daily intake of calcium decreased.
LS BMD was maintained, even with severe dairy
restrictions when calcium intake was maintained through
diet or supplementation.
Inflammatory bowel disease
Boot et al. [5] found decreased LS and TBBMD in
children with Crohn disease or ulcerative colitis. The
decreases were statistically significant even when they
accounted for the delayed bone age in their patients.
Similarly, Ahmed et al. [6] found reduced LS and TBBMD
Z-scores in nearly 70% of children with Crohn disease
and, to a lesser extent, ulcerative colitis, when compared
to healthy age-matched controls. However, when height
was taken into account, only 22% of their patients had low
BMD. Burnham et al. [7] found decreased height, lean
tissue mass and TBBMC in children with Crohn disease
when compared to normal controls. However, with
correction for height, age, race, Tanner stage and lean
tissue mass, no statistically significant differences were
found between the study and control groups. The authors
a l s of o u n dn oc o r r e l a t i o nb etween CS treatment and
height-corrected BMC. Similar findings were reported by
Walther et al. [8]. Thus, in patients with inflammatory
bowel disease, the apparent low LS BMD and TBBMC is
largely a result of short stature, delayed maturation and
decreased lean tissue mass.
Celiac disease
Kalayci et al. [9] found lower LS BMD in untreated celiac
disease patients compared to treated patients. They found
that nearly all children with celiac disease whose treatment
began before the age of 4 years reached normal BMD
compared to only 50% of children whose treatment began
after the age of 4 years. They also found that all patients
who initially presented with gastrointestinal symptoms had
normal BMD after 1 year of a gluten-free diet. In
prepubertal children with celiac disease, Barera et al. [10],
Tau et al. [11] and Szathmari et al. [12] found an increase in
height, weight, BMC and BMD after 1.5 years of a gluten-
free diet when compared to baseline measurements. These
reports indicate that in patients with celiac disease,
normalization of DXA findings can be expected with early
diagnosis and treatment.
Liver disease
The effects of liver dysfunction on bone health are complex
and may involve vitamin malabsorption, failure of vitamin
D activation, calcium malabsorption, bile salt deficiency
and chronic malnutrition. Argao et al. [13] evaluated
children with a variety of chronic cholestatic liver diseases
and found distal radial BMC to fall quickly after birth and
in infancy. The values remained low throughout childhood
and reflected the severity of the underlying hepatic
dysfunction. In a study of prepubertal children with Alagille
syndrome, Olsen et al. [14] found reduced height, weight
and TBBMC compared to healthy controls matched for age,
gender, ethnicity and physical maturity. Malabsorption of
fat-soluble vitamins, particularly vitamin D, significantly
reduces LS and TBBMC. D’Antiga et al. [15] found normal
LS BMC and BMD in patients with childhood liver failure
who were at least 1 year out from orthotopic liver transplan-
tation. Return to normal values appeared to be unaffected by
the severity of bone disease or cholestasis prior to transplan-
tation. Thus, liver dysfunction with disordered vitamin D
metabolism results in early decreased bone mineral accrual.
With successful liver transplantation, normalization of DXA
findings can be expected.
Renal diseases
Chronic kidney disease results in abnormal bone metabo-
lism via disturbances in calcium and phosphate handling,
altered vitamin D and parathyroid hormone levels and
function, and altered renal clearance of other metabolites.
Additional factors that affect the BMD in these patients
include malnutrition, metabolic acidosis, anemia and
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tion. As with many chronic medical conditions, short
stature will greatly affect BMD and needs to be accounted
for in DXA interpretation.
Bakr [16] found reduced LS BMD in 60% of pre- and
postdialysis patients. The degree of osteopenia correlated
with biochemical markers of secondary hyperparathyroid-
ism. However, the DXA BMD values were not corrected for
height. Similar results were reported by Pluskiewicz et al.
[17] following a 2-year longitudinal study of adolescents
with chronic kidney disease. They found decreased or stable
LS BMD (uncorrected for height) during a time when an
increase would be expected. The most severe decreases in
BMD were found in patients who were treated with CS. In
contrast, Ahmed et al. [18] found normal TBBMD and
TBBMC as well as normal LS BMD in children with
chronic kidney disease when the DXAvalues were corrected
for height. Similar findings were reported in children before
transplantation [19]. Boot et al. [20] reported normal LS and
TBBMD in patients with kidney disease of relatively short
duration and in the setting of adequate vitamin D replace-
ment. Two-year follow-up of these patients demonstrated
continued maintenance of normal BMD [21]. Several
authors found that the height-corrected LS BMD was
reduced for up to 2 years after transplantation; this was felt
to be due to high-dose CS treatment required to suppress
transplant rejection. However, by 3 years after transplanta-
tion, LS BMD had recovered to normal values [18, 22–24].
Idiopathic hypercalciuria results in excessive urinary
excretion of calcium and has increasingly been identified as
a cause of decreased BMD in children [25–28]. The degree
of BMD reduction does not appear to correlate with the
presence of urolithiasis or urinary uric acid concentration.
Studies of children and their mothers with idiopathic
hypercalciuria indicate that low LS and hip BMD persist
into adulthood [25, 26].
In summary, the various metabolic disturbances resulting
from altered renal physiology may compromise normal
bone mineralization and remodeling, but children with
chronic kidney disease often maintain normal BMD if
calcium and vitamin D metabolism are normal. CS treatment,
either before transplantation or when used to suppress
transplant rejection, appears to contribute to low BMD but
short-term follow-up indicates eventual normalization of LS
BMD. Regardless of the nature of renal disease, correcting
for height is essential for accurate interpretation of DXA
results in these patients.
Endocrinological diseases
Skeletal development is significantly influenced by multi-
ple hormone systems that are essential to normal bone
mineral accrual. Both insufficient and excessive hormone
levels can have deleterious effects, resulting in inadequate
bone formation or disproportionate bone resorption. Puber-
tal hormones play a critical role in bone mass acquisition
with major differences occurring based on sex and skeletal
site [29]. Patients with early or delayed puberty will show
early or delayed peak bone mass accrual, respectively [30].
Treatment of precocious puberty includes gonadotropin-
releasing hormone analogs that could theoretically interfere
with normal bone mineral acquisition. Short-term treatment
does not interfere with normal BMD increases in these
patients [31].
Disorders of growth hormone, insulin and glucocorticoids
Accurate DXA evaluation of children with growth hormone
deficiency or idiopathic short stature must account for their
smaller bones [1]. Children with growth hormone deficiency
will present with low areal [32] and volumetric LS [33]
BMD when first diagnosed. Children with idiopathic short
stature have also been found to have low areal LS and hip
BMD prior to therapy [34]. With sustained growth hormone
replacement these values have been reported to remain stable
[33]o rn o r m a l i z er a p i d l y[ 34]. Children with growth
hormone deficiency have a robust response to replacement
therapy with increases in height, lean tissue mass and
TBBMC [33]. Increases in BMD occur even after peak
height is achieved, and this indicates the need to continue
hormone therapy until peak BMD is achieved [35, 36].
Type 1 diabetes mellitus is a known risk factor for
osteoporosis, but the underlying mechanisms are not fully
determined. Adolescent patients have lower bone mass and
bone size despite normal growth and maturation [37].
Studies suggest that children and adolescents with diabetes
have reduced bone formation and increased bone resorption
resulting in low bone mass and BMD [38, 39]. Hemoglobin
A1C level, a measure of glycemic control, negatively
correlates with BMD [40] and TBBMC [41].
The negative effects of chronic high-dose CS therapy on
bone have been well documented. CS replacement therapy,
as in congenital adrenal hyperplasia, has not been found to
result in reduced BMD [42, 43]. However, young women
with congenital adrenal hyperplasia are at risk of reduced
BMD if there is biochemical evidence of androgen
suppression due to CS therapy [44]. Patients with either
childhood-onset or adult-onset Cushing disease often have
severe reductions in BMD due to increased osteoclastic
activity and bone resorption with normal or reduced bone
deposition [45]. Additionally, concomitant reductions in sex
and growth hormones contribute to their low BMD.
Adolescents appear to be particularly vulnerable to reduced
trabecular bone density as measured at the LS. BMD
deficits and biochemical measures of bone turnover showed
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cortisolism when compared to baseline values, but low LS
BMD persisted in the majority of patients [46].
Disorders of reproductive hormones
Reproductive hormones play an important role in the
acquisition of bone mineral; estrogen is known to have a
protective effect against the development of osteoporosis in
postmenopausal women. The effects of hormonal birth
control use on BMD in adolescent girls have been
investigated by several researchers. The trend toward lower
estrogen levels in oral contraceptives has been associated
with decreased BMD in adolescent girls who use oral
contraceptives [47, 48]. Progesterone-mediated contracep-
tives (Depo-Provera) have been shown to inhibit bone
mineral acquisition in the LS and hip in adolescent girls
[49–51]. The extent of this reduction appears to correlate
with the duration of treatment and can be lessened with
supplemental estrogen [51]. Partial or full BMD recovery
can occur after cessation of treatment and can be facilitated
with increased physical activity and adequate calcium and
vitamin D intake.
Girls with anorexia nervosa have been found to have
decreased BMD at multiple skeletal sites [52–54]. These
reductions are thought to be due to a combination of
nutritional (decreased calcium and caloric intake), hormonal
(decreased estrogen levels, delayed puberty), and mechanical
(decreased lean tissue mass) factors. With resumption of
normal caloric intake and return of menses, there is
biochemical evidence of increased bone turnover; however,
BMD levels remain low and Z-scores may continue to fall
for at least 1 year [53]. It is not known if full BMD recovery
will occur by early adulthood, but adult women who had
adolescent-onset anorexia nervosa have more dramatic
reductions in BMD than those with onset during adulthood
[55, 56]. Estrogen replacement with oral contraceptives and
vigorous exercise can protect against BMD loss in anorexia
nervosa [57].
Untreated congenital hypothyroidism can result in mark-
edly reduced BMD. Children with adequate long-term
thyroid replacement therapy show normal LS and hip
BMD and BMC [58, 59] and normal findings continue into
young adulthood [60]. Later in childhood, hypothyroidism is
usually caused by Hashimoto thyroiditis. LS and distal radial
BMD are expected to be normal at diagnosis and to be
maintained with thyroid hormone therapy, and normal peak
bone mass is to be expected in these patients [61]. Hyper-
thyroidism in Graves disease markedly decreases LS and hip
BMD, but these normalize within 1 year following thyroid
ablation and hormone therapy [62].
In summary, hormonal imbalances from any of a large
number of endocrine disorders are associated with abnor-
mal DXA findings and reduced BMD. With hormone
replacement therapy, improved bone mineral accrual is to
be expected in most of the endocrine deficiencies. Howev-
er, with anorexia nervosa, especially with onset in adoles-
cence, there appears to be a sustained reduction in BMD
even after resumption of normal caloric intake and menses.
Respiratory diseases
Cystic fibrosis
In cystic fibrosis (CF), low BMD may be caused by
reduced gastrointestinal absorption of calcium and vitamin
D, reduced testosterone levels, chronic hypoxia, chronic
CS use, and reduced lean tissue mass. Because of the
multifactorial nature of reduced BMD in CF, BMD Z-scores
often reflect the severity of illness. Clinically stable
c h i l d r e nw i t hm i l dC Fh a v eb e e ns h o w nt oh a v en o r m a l
BMD [63–65]. However, adolescents and adults with CF
have accelerated bone loss over time reflecting disease
progression [66, 67]. Henderson and Madsen [68]a n d
Buntain et al. [66] found progressively decreasing BMD
Z-scores with increasing age in CF patients. LS, hip and
TBBMD in the prepubertal group were normal. TBBMD
was reduced in adolescents; however, all other sites
remained normal. In adult patients, BMD was reduced at
all sites. In a follow-up study, Haworth et al. [69]r e p o r t e d
that patients older than 25 years showed accelerated LS
and hip BMD losses. Bhudhikanok et al. [70] found that
LS, hip, and TBBMD were low at baseline and docu-
mented further bone loss at follow-up. CS use was
identified as the most modifiable factor accounting for
this bone loss and the authors suggested that bisphospho-
nates may be beneficial in these patients. The benefits of
bisphosphonates in CF were confirmed by Aris et al. [71,
72] and Haworth et al. [73] who found increases in LS and
hip BMD following treatment with intravenous or oral
bisphosphonates, respectively.
Asthma
Asthma may inhibit normal bone metabolism due to
chronic hypoxia and decreased physical activity. Addition-
ally, asthmatic patients are treated with both oral and
inhaled CS to reduce airway inflammation. Patients treated
with low or moderate levels of inhaled CS have been
shown to have normal BMD Z-scores when compared to
CS-naive asthmatic controls but reduced BMD Z-scores
when compared to normal controls when height is not taken
into account [74–77]. Allen et al. [78] and Harris et al. [79]
found significant reductions in BMD in asthmatic children
receiving high doses of inhaled CS.
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Anemia and hemophilia
Chronic anemias can affect bone structure and density
through bone marrow hyperplasia (resulting in expansion of
the medullary space, trabecular coarsening and cortical
thinning), and vasoocclusion (resulting in medullary and
diaphyseal infarction). Additional factors for reduced BMD
include reduced lean tissue mass, decreased physical
activity and hypogonadism, and in the case of thalassemia,
endocrine dysfunction. Brinker et al. [80] found low BMD
in children with sickle cell anemia. These findings
confirmed those of Soliman et al. [81] who reported low
LS BMD in prepubertal children with sickle cell anemia.
Lal et al. [82] and Buison et al. [83] noted markedly
reduced BMD and BMC, which correlated with disease
severity in these children. These changes were found to
persist into adulthood [84]. Additionally, low calcium
intake and low vitamin D levels may contribute to
decreased BMD in these patients. Vogiatzi et al. [85] and
Benigno et al. [86] evaluated children with thalassemia
major who were fully treated with transfusion and chelation
therapy and found reduced BMD at diagnosis and showed
further reductions at follow-up.
Patients with hemophilia are at risk for osteoporosis due
to reduced levels of physical activity and sports, particu-
larly those involving running, jumping and axial loading of
the skeleton. The severity of hemophilic arthropathy can be
quantitated using a clinically derived joint score, and this
has been found to correlate with BMD [87]. Low BMD is
independent of height and weight but correlates with
disease severity and extent. These changes can be expected
to persist into adulthood [88].
Oncological diseases
Acute lymphocytic leukemia
ALL is the most common childhood malignancy, but
because of its excellent prognosis, most children with ALL
survive into adulthood. Arikoski et al. [89] found reduced
BMD in ALL survivors up to 20 years after treatment. Of
their 29 patients, 20 had received cranial irradiation and four
males had received testicular irradiation. The use of high-
dose methotrexate and cranial irradiation were found to be
significantly correlated with low BMD. Differing results
were presented by Brennan et al. [90] who also reported
significantly reduced LS, hip and distal radial BMD in long-
term survivors of ALL but found no statistically significant
correlation of BMD with cranial irradiation, growth hormone
status or height Z-scores. They suggested that the low BMD
found in their patients was related to the effects of
chemotherapy rather than cranial irradiation. Van der Sluis
et al. [91] found normal LS and TBBMD a mean of 10 years
after ALL treatment that included high-dose methotrexate
and CS but not cranial irradiation. Their patients had all been
prepubertal at the time of initial diagnosis and none had
signs of significant gonadal or growth hormone dysfunction
at the time of follow-up. The authors concluded that the
deleterious effects of ALL and its treatment in childhood on
BMD may be due to cranial irradiation but, in its absence,
BMD will normalize by early adulthood. This conclusion is
supported by other researchers [92, 93]. Jarfelt et al. [94]
examined bone turnover and growth hormone status with
respect to physical activity levels and BMD in adult
survivors of childhood ALL. The patients were all prepu-
bertal at the end of treatment and had been treated with high
doses of CS and methotrexate. No patient had evidence for
gonadal or endocrine dysfunction. The BMD values were
normal for the group. Only the level of physical fitness at
follow-up correlated positively with BMD. The authors
stressed the importance of physical activity in restoring and
maintaining normal BMD in survivors of childhood ALL.
In summary, children with ALL will have reduced BMD
during treatment and shortly thereafter. The recuperative
capacity in young children is high and normal BMD should
be expected even after high-dose methotrexate and CS
therapy. The role of adequate physical activity is being
increasingly stressed as an important factor in normal BMD
recovery. Children who have survived ALL may be at risk
of persistently low BMD in adulthood if they have
confounding factors such as gonadal dysfunction or if the
course of their disease coincided with the period of
expected rapid accrual of bone mineral that normally
occurs during puberty.
Other malignancies
There are only limited data regarding the effects of other
childhood malignancies on BMD. Aisenberg et al. [95] and
Vassilopoulou-Sellin et al. [96] found reduced femoral neck
and TBBMD in young adult survivors of various childhood
cancers. Gonadal dysfunction due to pelvic or cranial
irradiation was the factor most strongly correlated with
reduced BMD. CS treatment did not correlate with low
BMD. Nysom et al. [97] reported normal size-adjusted
TBBMC in adult survivors of childhood lymphoma and
found no relationship between TBBMC and cumulative
methotrexate or CS doses. Kelly et al. [98] evaluated adult
survivors of various pediatric solid tumors and found
reduced BMD in at least one site in half of their patients.
Only the total number of chemotherapeutic agents correlat-
ed with reduced BMD. Five of six extremities involved
with a bone sarcoma showed reduced BMD. Similar results
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Ruza et al. [99]. Interestingly, they found that those
diagnosed prior to puberty had more severe BMD reduc-
tions later in life. This may be due to the extensive physical
disabilities associated with amputations and limb salvage
procedures in these patients. Odame et al. [100] found that
patients with childhood brain tumors treated with cranial
irradiation had reduced LS and TBBMD and these were
correlated with reduced physical activity and poorer quality
of life. The authors postulated that the higher cranial
radiation doses used for the treatment of brain tumors had
a profound effect on long-term BMD compared to the
relatively lower doses used in the treatment of ALL.
Insummary, there are multiplefactors thataffectshort-and
long-term BMD in these patients/survivors. These include
pubertal status at diagnosis, type of malignancy, local
(sarcomas, central nervous system tumors) versus systemic
(leukemia) disease, initial (malnutrition, immobilization)
versus prolonged (amputation) disease-related disability,
types of chemotherapy, and radiation ports and dosages that
may cause gonadal or growth hormonal dysfunction.
Neurological diseases
Cerebral palsy
Because of decreased muscle development and ambulation,
children with cerebral palsy are at increased risk of
osteoporosis-associated fractures. Frequently, assessment of
the LS and hips with DXA is impossible due to difficulties in
positioning patients with contraction deformities, muscular
spasm-induced motion artifacts or orthopedic hardware-
related artifacts. Because of these limitations, Harcke et al.
[101] suggested scanning the distal femur with these
patients positioned on their side. Distal femoral BMD was
found to be highly correlated with hip BMD and the
technique yielded highly reproducible BMD data [102].
Henderson et al. [103] demonstrated reduced LS and hip
BMD in children with cerebral palsy. Measures of
nutritional and ambulatory status were found to be the best
predictors of BMD. In children with moderate to severe
disease, Henderson et al. [104] found distal femur and LS
BMD to be markedly reduced and both closely correlated
with disease severity. Distal femoral BMD was negatively
correlated with age, indicating progressive bone mineral
deficits as these children grew older. The lack of a strong
correlation between LS BMD and fracture risk in the lower
extremities emphasizes the need for direct assessment of the
distal femur with DXA in these patients. In a prospective
longitudinal study of patients with cerebral palsy, Henderson
et al. [105] found that low initial LS and distal femur BMD
Z-scores were associated with poor growth, nutritional status
and motor function, and these contributed to reduced bone
mineralization at follow-up. Treatment with bisphosphonates
for 1 year resulted in a substantial increase in distal femoral
BMD in children with quadriplegic cerebral palsy [106]. The
improvement was sustained for at least 6 months after the
last treatment. However, Bachrach et al. [107] found that LS
BMD returned to baseline values 2 years after bisphospho-
nate therapy was terminated. Importantly, despite the lack of
sustained BMD improvement, no patient had a fracture
during the treatment or follow-up periods.
In summary, children with CP show decreased bone
mineral status that reflects the duration and severity of their
disease. Distal femoral measurements better reflect the bone
status at the sites more at risk of fracture. Bisphosphonate
therapy increases BMD during treatment and it appears to
have sustained benefits with reduced fracture rates even
after treatment is terminated.
Meningomyelocele
Quan et al. [108] found reduced forearm BMD in children
with meningomyelocele. Patients with a history of fracture
had substantially lower forearm BMD than those without a
fracture history. The reduced upper extremity BMD in these
patients with preserved upper extremity function may
indicate that both systemic and local factors affect bone
mineralization. Hypercalciuria in nonambulatory patients
with meningomyelocele may be such a factor. Quan et al.
[109] later evaluated the effect of thiazide treatment for
hypercalciuria in these patients and found no change after
1 year in forearm BMD when compared to placebo-treated
controls. Valtonen et al. [110] found normal forearm and LS
BMD in adult patients with meningomyelocele, but reduced
hip BMD in one-third of the patients. There was a trend for
low hip BMD in the nonambulatory compared to ambula-
tory patients but not for the LS. This dissociation of LS and
hip BMD values was thought to be due to relatively
preserved axial loading on the LS in upright patients with
meningomyelocele. The normalization of forearm BMD in
these adult patients was attributed to increased upper
extremity muscular stress with the use of crutches and
manual wheelchairs.
Connective tissue diseases
Juvenile rheumatoid arthritis and systemic lupus
erythematosus
Rheumatoid diseases have long been known to affect bone
health negatively. Disease extent, severity, subsequent
disability and CS therapy negatively impact bone mineral-
ization. Pepmueller et al. [111] and Pereira et al. [112]
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JRA. The decrease was more severe in children with longer
disease duration and was similar for oligoarthritis and
polyarthritis. Lien et al. [113] found decreased TBBMC and
TBBMD in patients with juvenile idiopathic arthritis.
Disease duration and severity correlated with TBBM but
not CS therapy. Henderson et al. [114] found no statistically
significant difference in TBBMD in prepubertal children
with mild-to-moderate JRA and no history of CS treatment
when compared to normal controls. When a similar study
was performed on CS-naive older girls with mild-to-
moderate JRA, Henderson et al. [115] found decreased
TBBMC. As with other chronic diseases of childhood, it
appears that persistent disease activity through puberty
results in decreased BMC. Mul et al. [116] found marked
reductions in LS BMD and BMC in children with rheumatic
diseases treated for at least 1 year with high-dose CS.
Bianchi et al. [117] found that long-term methotrexate for
JRA did not result in reduced LS or TBBMD.
In summary, prepubertal children with JRA of mild or
moderate severity without a history of CS treatment will
have TBBMD similar to healthy children. With increasing
disease severity and duration, especially through puberty,
TBBMC will decrease when compared to normal children.
These changes are in contrast to the normal DXA
findings reported in patients with juvenile systemic lupus
erythematosus [118, 119]. Unlike patients with JRA, these
patients typically do not have bone and joint involvement
and thus are more likely to have preserved BMD. However,
factors that may negatively impact bone health in these
patients include immobility, limited exposure to sunlight,
and CS therapy.
Musculoskeletal diseases
For normal mineralization to occur, adequate muscle-
induced mechanical stresses are required to induce bony
remodeling. Insufficient muscle mass and activity result in
poor bone accrual and low BMD. Additionally, therapy of
primary muscle disorders with CS also inhibits normal bone
mineralization.
Duchenne muscular dystrophy and dermatomyositis
In a longitudinal study of boys with Duchenne muscular
dystrophy, Larson and Henderson [120] found that LS and
hip BMD correlated with functional mobility level with
ambulatory boys having higher LS BMD than nonambula-
tory boys. Hip BMD was decreased before loss of
ambulation and showed progressive reduction over time.
Fractures occurred in nearly half of patients, most typically
involving the lower extremity and frequently resulting in loss
of ambulation. Bianchi et al. [121] found decreased LS and
TBBMD in ambulatory boys with Duchenne muscular
dystrophy when compared to healthy boys. LS BMD was
more severely reduced in the subset of Duchenne muscular
dystrophy patients treated with CS. The authors noted greater
lower extremity than upper extremity bone mineral loss using
regional DXA analysis, especially in the CS-treated patients,
and they attributed this to reduced mechanical stress on the
lower extremities. Hawker et al. [122] found an increase in
LS and TBBMD after 2 years of bisphosphonate treatment,
supplemental calcium, and vitamin D. Improvement in
TBBMD was inversely related to age at baseline.
In summary, patients with Duchenne muscular dystrophy
have reduced LS BMD, especially in the setting of CS
treatment. The low LS and hip BMD worsen with loss of
ambulatory status and are frequently associated with
fractures of the lower extremities.
Studies of a small number of children with dermatomyo-
sitis have found low LS BMD that worsens with ongoing CS
therapy [123, 124]. Patients treated with bisphosphonates for
osteoporosis-related compression fractures show increases in
LS BMD [123].
Osteogenesis imperfecta
Osteogenesis imperfecta includes a spectrum of genetic
disorders of collagen synthesis resulting in abnormal
skeletal and connective tissues. Reduced BMD and other
factors result in fragile bones and multiple fractures.
Fracture occurrence and DXA findings in these children
vary with subtype with few fractures and normal or near-
normal DXA findings in type I osteogenesis imperfecta and
more frequent fractures and marked reductions in BMD in
types III and IV [125, 126]. (Type II typically results in
perinatal demise.) Since as many as 40% of patients with
osteogenesis imperfecta will have normal BMD and BMC,
a normal DXA study does not preclude this diagnosis or
distinguish these cases from non-accidental injuries [125].
In recent years, clinical trials using bisphosphonates in
osteogenesis imperfecta have yielded impressive results
with multiple studies demonstrating increases in LS, hip
and TBBMD and improved quality of life [127–130].
Patients with the lowest baseline bone mass experienced the
most significant gains with treatment. Improved mobility,
ambulation, muscle force and reduced chronic pain and
fatigue lead to improved quality of life, and the stimulus of
physical activity is known to be beneficial to bone.
Increased bone mass in the skull following bisphosphonate
therapy in these patients implies that the drug also has a
direct effect on bone accrual irrespective of physical
activity [129]. The theoretical concern that this therapy
might negatively impact linear growth in these children has
not been shown to be true [131].
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